Cuiqiong Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cuiqiong Dai has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Yumin Zhou
State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
16 shared publications - Fan Wu
State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
14 shared publications - Pixin Ran
State Key Laboratory of Respiratory Diseases National Clinical Research Center for Respiratory Diseases Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China
14 shared publications Changli Yang
Wengyuan County People's Hospital, Shaoguan, China
10 shared publicationsShuqing Yu
Lianping County People's Hospital, Heyuan, China
10 shared publicationsXiaohui Wu
State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
10 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Clinical Characteristics and Outcomes of Chronic Obstructive Pulmonary Disease Patients with Expiratory Central Airway Collapse: A Prospective Community-based Cohort Study in China
Background: Expiratory central airway collapse (ECAC) may represent an imaging-defined marker of chronic obstructive pulmonary disease (COPD). However, evidence regarding the clinical significance of ECAC in COPD remains limited. Therefore, we aimed to evaluate the presence of ECAC in patients with COPD and its association with respiratory health outcomes. Methods: This study included patients with COPD from a prospective, community-based cohort. The patients underwent spirometry, questionnaires, and paired inspiratory/expiratory chest computed tomography at baseline, and annual exacerbation assessment and spirometry during the 3-year follow-up. ECAC was defined as a reduction in airway cross-sectional area of ≥50% during end-expiration compared with the area during end-inspiration at any of three anatomical levels: the aortic arch, carina, and bronchus intermedius. The outcomes were exacerbation risk and annual rate of lung function decline. Results: 915 patients with COPD were included in the baseline analysis, 892 completed 3-year follow-up. The ECAC detection rate among patients with COPD was 8.7% (80/915). Patients with ECAC had higher total exacerbation (RR=1.50, 95%CI: 1.11–2.04, p=0.009) and moderate-to-severe exacerbation (RR=1.50, 95%CI: 1.07–2.09, p=0.017) risks than those without ECAC. With each additional anatomical level of ECAC, total (RR=1.22, 95%CI: 1.06–1.41, p=0.006) and moderate-to-severe (RR=1.18, 95%CI: 1.01–1.39, p=0.043) exacerbation risks increased. No significant difference was found in lung function decline between patients with and without ECAC. Conclusion: ECAC was associated with a higher exacerbation risk among patients with COPD, suggesting that ECAC may serve as an imaging-based prognostic marker of COPD to guide future exacerbation risk assessment.
- 6 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessClinical Characteristics and Outcomes of Chronic Obstructive Pulmonary Disease Patients with Expiratory Central Airway Collapse: A Prospective Community-based Cohort Study in China
Background: Expiratory central airway collapse (ECAC) may represent an imaging-defined marker of chronic obstructive pulmonary disease (COPD). However, evidence regarding the clinical significance of ECAC in COPD remains limited. Therefore, we aimed to evaluate the presence of ECAC in patients with COPD and its association with respiratory health outcomes. Methods: This study included patients with COPD from a prospective, community-based cohort. The patients underwent spirometry, questionnaires, and paired inspiratory/expiratory chest computed tomography at baseline, and annual exacerbation assessment and spirometry during the 3-year follow-up. ECAC was defined as a reduction in airway cross-sectional area of ≥50% during end-expiration compared with the area during end-inspiration at any of three anatomical levels: the aortic arch, carina, and bronchus intermedius. The outcomes were exacerbation risk and annual rate of lung function decline. Results: 915 patients with COPD were included in the baseline analysis, 892 completed 3-year follow-up. The ECAC detection rate among patients with COPD was 8.7% (80/915). Patients with ECAC had higher total exacerbation (RR=1.50, 95%CI: 1.11–2.04, p=0.009) and moderate-to-severe exacerbation (RR=1.50, 95%CI: 1.07–2.09, p=0.017) risks than those without ECAC. With each additional anatomical level of ECAC, total (RR=1.22, 95%CI: 1.06–1.41, p=0.006) and moderate-to-severe (RR=1.18, 95%CI: 1.01–1.39, p=0.043) exacerbation risks increased. No significant difference was found in lung function decline between patients with and without ECAC. Conclusion: ECAC was associated with a higher exacerbation risk among patients with COPD, suggesting that ECAC may serve as an imaging-based prognostic marker of COPD to guide future exacerbation risk assessment.
- Open Access
- 16 April 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003918
Long-term variability of impulse oscillometry defined small airway dysfunction in participants with and without chronic obstructive pulmonary disease
Background: Small airway dysfunction (SAD), as assessed by impulse oscillometry (IOS) (IOS-SAD), exhibits temporal variability and its long-term fluctuations may be linked to distinct clinical phenotypes. We investigated the associations of long-term variability in IOS-SAD with adverse clinical outcomes among participants with and without chronic obstructive pulmonary disease (COPD). Methods: The baseline and 2-year follow-up data from the early COPD cohort were retrospectively analysed. SAD was defined based on the following criteria: difference from R5 to R20 (R5-R20) >upper limit of normal (ULN) (R5-R20-SAD), or reactance at 5 Hz (X5) ULN. Individuals were classified into three groups based on SAD variability over three visits at 2-year follow-up: (1) consistent SAD (SAD at every visit), (2) inconsistent SAD (SAD at some, but not all, visits) and (3) never SAD (no SAD at any visit). Differences in the rate of spirometric lung function decline and exacerbation rate were compared across long-term IOS-SAD variability groups in participants with and without COPD. Results: In individuals with COPD, the consistent and inconsistent SAD groups assessed were associated with a faster spirometric lung function decline and a higher risk of exacerbations. In individuals without COPD, the consistent R5-R20-SAD group was associated with a faster decline in spirometric lung function and progression towards COPD. Conclusions: SAD, even diagnosed once, characterises an airway behaviour with a higher proportion of higher risk of moderate or severe exacerbations. Consistent SAD was associated with accelerated spirometric lung function decline, increased exacerbation risk and progression to spirometry-defined COPD. Trial registration number: ChiCTR1900024643.
- 16 April 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e003918
Open AccessLong-term variability of impulse oscillometry defined small airway dysfunction in participants with and without chronic obstructive pulmonary disease
Background: Small airway dysfunction (SAD), as assessed by impulse oscillometry (IOS) (IOS-SAD), exhibits temporal variability and its long-term fluctuations may be linked to distinct clinical phenotypes. We investigated the associations of long-term variability in IOS-SAD with adverse clinical outcomes among participants with and without chronic obstructive pulmonary disease (COPD). Methods: The baseline and 2-year follow-up data from the early COPD cohort were retrospectively analysed. SAD was defined based on the following criteria: difference from R5 to R20 (R5-R20) >upper limit of normal (ULN) (R5-R20-SAD), or reactance at 5 Hz (X5) ULN. Individuals were classified into three groups based on SAD variability over three visits at 2-year follow-up: (1) consistent SAD (SAD at every visit), (2) inconsistent SAD (SAD at some, but not all, visits) and (3) never SAD (no SAD at any visit). Differences in the rate of spirometric lung function decline and exacerbation rate were compared across long-term IOS-SAD variability groups in participants with and without COPD. Results: In individuals with COPD, the consistent and inconsistent SAD groups assessed were associated with a faster spirometric lung function decline and a higher risk of exacerbations. In individuals without COPD, the consistent R5-R20-SAD group was associated with a faster decline in spirometric lung function and progression towards COPD. Conclusions: SAD, even diagnosed once, characterises an airway behaviour with a higher proportion of higher risk of moderate or severe exacerbations. Consistent SAD was associated with accelerated spirometric lung function decline, increased exacerbation risk and progression to spirometry-defined COPD. Trial registration number: ChiCTR1900024643.
- Open Access
- 9 April 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (4)
Association of PiSlope with lung function decline in individuals with preserved spirometry: a prospective cohort study
Background: Airway remodeling precedes airflow obstruction in chronic obstructive pulmonary disease. Pi 10 assumes a consistent fixed slope between airway wall thickness and lumen perimeter across individuals. PiSlope comprehensively quantifies airway wall thickening, which is associated with increased acute exacerbation and mortality risk. Whether PiSlope is associated with respiratory prognosis in participants with preserved spirometry is unknown. Methods: Participants with preserved spirometry with complete baseline questionnaires, spirometry, and chest computed tomography were enrolled from a 3–year prospective ECOPD cohort study and divided into four groups by PiSlope quartile (Q) (Q1: PiSlope≥0.4946, Q2: 0.4550≤PiSlope1 ) (adjusted difference 5 mL/year, 95% confidence interval [CI] 1–9, p=0.007) and postbronchodilator FEV 1 (adjusted difference 4 mL/year, 95% CI 0–9, p=0.033), and increased airflow obstruction risk (unadjusted odds ratio [OR] 1.21, 95% CI 1.01–1.36, p =0.038). Q2–Q4 had accelerated decline in prebronchodilator FEV 1 and FEV 1 % predicted than Q1 (all p<0.05). The third-year risk of airflow obstruction progression was higher in Q2 (adjusted OR 2.40, 95% CI 1.13–5.08, p=0.022), Q3 (adjusted OR 1.71, 95% CI 0.77–3.82, p=0.188), and Q4 (adjusted OR 2.04, 95% CI 0.92–4.53, p=0.078) than in Q1. Conclusion: Lower PiSlope was associated with faster lung function decline and increased airflow obstruction risk in participants with preserved spirometry, but the association between PiSlope and progression to airflow obstruction was not significant after adjustment.
- 9 April 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (4)
Open AccessAssociation of PiSlope with lung function decline in individuals with preserved spirometry: a prospective cohort study
Background: Airway remodeling precedes airflow obstruction in chronic obstructive pulmonary disease. Pi 10 assumes a consistent fixed slope between airway wall thickness and lumen perimeter across individuals. PiSlope comprehensively quantifies airway wall thickening, which is associated with increased acute exacerbation and mortality risk. Whether PiSlope is associated with respiratory prognosis in participants with preserved spirometry is unknown. Methods: Participants with preserved spirometry with complete baseline questionnaires, spirometry, and chest computed tomography were enrolled from a 3–year prospective ECOPD cohort study and divided into four groups by PiSlope quartile (Q) (Q1: PiSlope≥0.4946, Q2: 0.4550≤PiSlope1 ) (adjusted difference 5 mL/year, 95% confidence interval [CI] 1–9, p=0.007) and postbronchodilator FEV 1 (adjusted difference 4 mL/year, 95% CI 0–9, p=0.033), and increased airflow obstruction risk (unadjusted odds ratio [OR] 1.21, 95% CI 1.01–1.36, p =0.038). Q2–Q4 had accelerated decline in prebronchodilator FEV 1 and FEV 1 % predicted than Q1 (all p<0.05). The third-year risk of airflow obstruction progression was higher in Q2 (adjusted OR 2.40, 95% CI 1.13–5.08, p=0.022), Q3 (adjusted OR 1.71, 95% CI 0.77–3.82, p=0.188), and Q4 (adjusted OR 2.04, 95% CI 0.92–4.53, p=0.078) than in Q1. Conclusion: Lower PiSlope was associated with faster lung function decline and increased airflow obstruction risk in participants with preserved spirometry, but the association between PiSlope and progression to airflow obstruction was not significant after adjustment.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 3791-3802
Reduced FEV3/FVC as an Early Indicator of COPD in Individuals with Normal Spirometry: A Prospective Analysis from the ECOPD Study
Purpose: This study aimed to evaluate the association between the forced expiratory volume in 3 s (FEV3) to forced vital capacity (FVC) and computed tomography (CT)-defined abnormalities, and to assess its potential value in predicting incident chronic obstructive pulmonary disease (COPD) over a 3-year period. Participants and Methods: This 3-year community-based cohort study enrolled participants with normal lung function (post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted). Baseline assessments included questionnaires, spirometry, CT scans, and impulse oscillometry. Participants were stratified by post-bronchodilator FEV3/FVC tertiles. Outcomes included acute respiratory events, annual lung function decline, and COPD incidence. Data were analyzed using mixed-effects models, log-binomial regression, and zero-inflated negative binomial models. Results: Of the 981 participants with normal baseline lung function stratified by post-bronchodilator FEV3/FVC tertiles (high: ≥ 95.5%, medium: 91.9– 95.4%, low: ≤ 91.8%), 807 completed the 3-year follow-up. Compared to the high-FEV3/FVC group, participants in the low-FEV3/FVC group tended to be older (60.5 vs 55.7 years) and included more males (80.4% vs 38.8%) and smokers. The low-FEV3/FVC group also demonstrated a lower baseline post-bronchodilator FEV1/FVC (74.0% vs 85.1%) and higher prevalence of emphysema (53.5% vs 18.3%). Longitudinal analysis revealed a greater annual post-bronchodilator FEV1 decline in the low-FEV3/FVC group (adjusted mean difference: 10 mL, 95% confidence interval [CI]: 0 to 21mL; p = 0.043) and an increased risk of developing COPD (19.4% versus 1.9%; adjusted relative risk: 4.96, 95% CI: 1.96– 12.51; p = 0.001) than the high-FEV3/FVC group, with no difference in acute respiratory events. Conclusion: A reduced FEV3/FVC ratio was associated with an increased risk of accelerated lung function decline and progression to COPD in individuals with normal spirometry. As a readily accessible measure derived from routine spirometry, FEV3/FVC may have a role in early COPD detection.
- 1 November 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 3791-3802
Open AccessReduced FEV3/FVC as an Early Indicator of COPD in Individuals with Normal Spirometry: A Prospective Analysis from the ECOPD Study
Purpose: This study aimed to evaluate the association between the forced expiratory volume in 3 s (FEV3) to forced vital capacity (FVC) and computed tomography (CT)-defined abnormalities, and to assess its potential value in predicting incident chronic obstructive pulmonary disease (COPD) over a 3-year period. Participants and Methods: This 3-year community-based cohort study enrolled participants with normal lung function (post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted). Baseline assessments included questionnaires, spirometry, CT scans, and impulse oscillometry. Participants were stratified by post-bronchodilator FEV3/FVC tertiles. Outcomes included acute respiratory events, annual lung function decline, and COPD incidence. Data were analyzed using mixed-effects models, log-binomial regression, and zero-inflated negative binomial models. Results: Of the 981 participants with normal baseline lung function stratified by post-bronchodilator FEV3/FVC tertiles (high: ≥ 95.5%, medium: 91.9– 95.4%, low: ≤ 91.8%), 807 completed the 3-year follow-up. Compared to the high-FEV3/FVC group, participants in the low-FEV3/FVC group tended to be older (60.5 vs 55.7 years) and included more males (80.4% vs 38.8%) and smokers. The low-FEV3/FVC group also demonstrated a lower baseline post-bronchodilator FEV1/FVC (74.0% vs 85.1%) and higher prevalence of emphysema (53.5% vs 18.3%). Longitudinal analysis revealed a greater annual post-bronchodilator FEV1 decline in the low-FEV3/FVC group (adjusted mean difference: 10 mL, 95% confidence interval [CI]: 0 to 21mL; p = 0.043) and an increased risk of developing COPD (19.4% versus 1.9%; adjusted relative risk: 4.96, 95% CI: 1.96– 12.51; p = 0.001) than the high-FEV3/FVC group, with no difference in acute respiratory events. Conclusion: A reduced FEV3/FVC ratio was associated with an increased risk of accelerated lung function decline and progression to COPD in individuals with normal spirometry. As a readily accessible measure derived from routine spirometry, FEV3/FVC may have a role in early COPD detection.
- Open Access
- 20 October 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003161
Assessment of the clinical prognosis of patients with chronic obstructive pulmonary disease using combined blood and sputum eosinophil counts
Background: High blood or sputum eosinophil counts are linked to poor clinical outcomes in chronic obstructive pulmonary disease (COPD), yet the value of combining both for the assessment of clinical prognosis remains unclear. In this study, we explore the value of combined blood and sputum eosinophil counts for assessing COPD outcomes. Methods: Patients were divided into four groups by blood (≥300 cells/µL) and sputum (≥3%) eosinophil counts (low blood and low sputum, low blood and high sputum, high blood and low sputum, high blood and high sputum). Spirometry, questionnaires, CT scans, impulse oscillometry, blood laboratory tests and induced sputum tests were performed at baseline. Spirometry and follow-up questionnaires were performed annually. Poisson regression was used to compute the relative risk (RR) for acute exacerbation. The mixed-effects model was used to assess annual lung function decline. Results: Compared with the low blood and low sputum eosinophils group, the high blood and high sputum eosinophils group had poorer lung function, more severe airway resistance and worse emphysema and air trapping at baseline. The high blood and high sputum eosinophils group had higher risks of cough (adjusted OR=1.87, 95% CI 1.20 to 2.92, p=0.006) and wheezing (adjusted OR=2.19, 95% CI 1.32 to 3.64, p=0.002). The low blood and high sputum eosinophils group had higher risks of phlegm (adjusted OR=1.53, 95% CI 1.04 to 2.24, p=0.029) and dyspnoea (adjusted OR=1.68, 95% CI 1.13 to 2.50, p=0.010). The high blood and high sputum eosinophils group demonstrated higher total (adjusted RR=1.36, 95% CI 1.15 to 1.60, p<0.001) and moderate-to-severe (adjusted RR=1.42, 95% CI 1.14 to 1.76, p=0.001) exacerbation risks. There was no significant difference in annual lung function decline among the groups. Conclusion: Elevated blood and sputum eosinophil counts are linked to worse lung function and a higher exacerbation risk in patients with COPD.
- 20 October 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003161
Open AccessAssessment of the clinical prognosis of patients with chronic obstructive pulmonary disease using combined blood and sputum eosinophil counts
Background: High blood or sputum eosinophil counts are linked to poor clinical outcomes in chronic obstructive pulmonary disease (COPD), yet the value of combining both for the assessment of clinical prognosis remains unclear. In this study, we explore the value of combined blood and sputum eosinophil counts for assessing COPD outcomes. Methods: Patients were divided into four groups by blood (≥300 cells/µL) and sputum (≥3%) eosinophil counts (low blood and low sputum, low blood and high sputum, high blood and low sputum, high blood and high sputum). Spirometry, questionnaires, CT scans, impulse oscillometry, blood laboratory tests and induced sputum tests were performed at baseline. Spirometry and follow-up questionnaires were performed annually. Poisson regression was used to compute the relative risk (RR) for acute exacerbation. The mixed-effects model was used to assess annual lung function decline. Results: Compared with the low blood and low sputum eosinophils group, the high blood and high sputum eosinophils group had poorer lung function, more severe airway resistance and worse emphysema and air trapping at baseline. The high blood and high sputum eosinophils group had higher risks of cough (adjusted OR=1.87, 95% CI 1.20 to 2.92, p=0.006) and wheezing (adjusted OR=2.19, 95% CI 1.32 to 3.64, p=0.002). The low blood and high sputum eosinophils group had higher risks of phlegm (adjusted OR=1.53, 95% CI 1.04 to 2.24, p=0.029) and dyspnoea (adjusted OR=1.68, 95% CI 1.13 to 2.50, p=0.010). The high blood and high sputum eosinophils group demonstrated higher total (adjusted RR=1.36, 95% CI 1.15 to 1.60, p<0.001) and moderate-to-severe (adjusted RR=1.42, 95% CI 1.14 to 1.76, p=0.001) exacerbation risks. There was no significant difference in annual lung function decline among the groups. Conclusion: Elevated blood and sputum eosinophil counts are linked to worse lung function and a higher exacerbation risk in patients with COPD.
- Open Access
- 14 October 2025
- Published by Taylor & Francis in Pulmonology
- Vol. 31 (1) , 2572011
Prevalence, risk factors, and clinical implications of failed spirometry in adults: Results from NHANES 2007–2012
Some participants inevitably fail spirometry testing and we aimed to assess the prevalence, risk factors, chronic respiratory symptoms, health status, and all-cause mortality outcomes associated with failed spirometry. Using NHANES 2007-2012 data, we categorized participants into three groups: those with failed spirometry (FS-participants), those with qualified spirometry without COPD (QS-non-COPD), and those with qualified spirometry and COPD (QS-COPD). We assessed the prevalence and risk factors associated with FS-participants and compared clinical implications among the three groups. The prevalence of FS-participants was 4.8%. Key risk factors included older age, being male, non-Hispanic Black ethnicity, lower socioeconomic status, self-reported emphysema, and increased frailty. After adjustment, FS-participants had higher odds of shortness of breath, wheezing, and dry cough at night (all P values < 0.05). They also faced a greater risk of all-cause mortality (HR: 1.51, 95% CI: 1.22 to 1.86; p < 0.001) compared to the QS-non-COPD group, a risk similar to that of the QS-COPD group (HR: 1.05, 95% CI: 0.82 to 1.27; p = 0.675). Failed spirometry is common among adults and correlates with increased respiratory symptoms and higher all-cause mortality risk, indicating the need for targeted attention.
- 14 October 2025
- Published by Taylor & Francis in Pulmonology
- Vol. 31 (1) , 2572011
Open AccessPrevalence, risk factors, and clinical implications of failed spirometry in adults: Results from NHANES 2007–2012
Some participants inevitably fail spirometry testing and we aimed to assess the prevalence, risk factors, chronic respiratory symptoms, health status, and all-cause mortality outcomes associated with failed spirometry. Using NHANES 2007-2012 data, we categorized participants into three groups: those with failed spirometry (FS-participants), those with qualified spirometry without COPD (QS-non-COPD), and those with qualified spirometry and COPD (QS-COPD). We assessed the prevalence and risk factors associated with FS-participants and compared clinical implications among the three groups. The prevalence of FS-participants was 4.8%. Key risk factors included older age, being male, non-Hispanic Black ethnicity, lower socioeconomic status, self-reported emphysema, and increased frailty. After adjustment, FS-participants had higher odds of shortness of breath, wheezing, and dry cough at night (all P values < 0.05). They also faced a greater risk of all-cause mortality (HR: 1.51, 95% CI: 1.22 to 1.86; p < 0.001) compared to the QS-non-COPD group, a risk similar to that of the QS-COPD group (HR: 1.05, 95% CI: 0.82 to 1.27; p = 0.675). Failed spirometry is common among adults and correlates with increased respiratory symptoms and higher all-cause mortality risk, indicating the need for targeted attention.
- 6 August 2025
- Published by Wiley in Respirology
- Vol. 30 (11) , 1056-1067
Elevated MMP ‐9 Is Associated With Accelerated Lung Function Decline and COPD Development: A Prospective Cohort Study and Mendelian Randomisation Analysis
Background and Objective: The imbalance in proteases/antiproteases caused by inflammation contributes to COPD, and matrix metalloproteinase‐9 (MMP‐9) may play an important role. Therefore, we aimed to investigate the associations of MMP‐9 with respiratory health outcomes. Methods: This study was conducted in two parts. Firstly, we performed a prospective cohort study to investigate the association of circulating MMP‐9 and respiratory health outcomes. Participants completed a questionnaire, spirometry, and chest CT, and provided blood samples at baseline. Follow‐up visits were conducted annually. Study outcomes were the development of spirometry‐defined COPD, lung function decline, and exacerbations. Secondly, we performed a two‐sample Mendelian randomisation (MR) study to evaluate the causal effect between genetically predicted MMP‐9 expression and lung function. Results: Overall, 1328 participants were included in the baseline analysis, and 1034 (78%) completed the 2‐year follow‐up. Higher plasma MMP‐9 at baseline was associated with chronic respiratory symptoms, severe emphysema, and air trapping. During the 2‐year follow‐up, each SD increase in plasma MMP‐9 was associated with accelerated decline in pre‐bronchodilator FEV 1 (adjusted difference = 6.4 [95% CI: 0.7–12.1] mL/year) and FVC (adjusted difference = 18.0 [95% CI: 7.6–28.5] mL/year), and a higher exacerbation incidence. In participants with normal spirometry at baseline, higher plasma MMP‐9 was associated with progression to spirometry‐defined COPD (adjusted OR = 1.93, 95% CI: 1.05–3.57). A MR study demonstrated similar results toward negative associations of genetically predicted MMP‐9 expression with FEV 1 and FVC. Conclusion: The longitudinal cohort and MR study provide evidence that MMP‐9 might play a causative role in lung function decline and spirometry‐defined COPD development. image
- 6 August 2025
- Published by Wiley in Respirology
- Vol. 30 (11) , 1056-1067
Elevated MMP ‐9 Is Associated With Accelerated Lung Function Decline and COPD Development: A Prospective Cohort Study and Mendelian Randomisation Analysis
Background and Objective: The imbalance in proteases/antiproteases caused by inflammation contributes to COPD, and matrix metalloproteinase‐9 (MMP‐9) may play an important role. Therefore, we aimed to investigate the associations of MMP‐9 with respiratory health outcomes. Methods: This study was conducted in two parts. Firstly, we performed a prospective cohort study to investigate the association of circulating MMP‐9 and respiratory health outcomes. Participants completed a questionnaire, spirometry, and chest CT, and provided blood samples at baseline. Follow‐up visits were conducted annually. Study outcomes were the development of spirometry‐defined COPD, lung function decline, and exacerbations. Secondly, we performed a two‐sample Mendelian randomisation (MR) study to evaluate the causal effect between genetically predicted MMP‐9 expression and lung function. Results: Overall, 1328 participants were included in the baseline analysis, and 1034 (78%) completed the 2‐year follow‐up. Higher plasma MMP‐9 at baseline was associated with chronic respiratory symptoms, severe emphysema, and air trapping. During the 2‐year follow‐up, each SD increase in plasma MMP‐9 was associated with accelerated decline in pre‐bronchodilator FEV 1 (adjusted difference = 6.4 [95% CI: 0.7–12.1] mL/year) and FVC (adjusted difference = 18.0 [95% CI: 7.6–28.5] mL/year), and a higher exacerbation incidence. In participants with normal spirometry at baseline, higher plasma MMP‐9 was associated with progression to spirometry‐defined COPD (adjusted OR = 1.93, 95% CI: 1.05–3.57). A MR study demonstrated similar results toward negative associations of genetically predicted MMP‐9 expression with FEV 1 and FVC. Conclusion: The longitudinal cohort and MR study provide evidence that MMP‐9 might play a causative role in lung function decline and spirometry‐defined COPD development. image
- Open Access
- 10 June 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Impulse oscillometry-defined airway abnormalities as a treatable trait for mild-to-moderate COPD: a prospective cohort study with 3-year follow-up
Background: Treatable traits (TTs) can effectively conduct personalised assessment and treatment for patients with mild-to-moderate COPD. After excluding the classic TTs, do some neglected TTs remain? We evaluated associations of impulse oscillometry (IOS)-defined airway abnormalities (AAs) with respiratory health outcomes and prognoses in patients with mild-to-moderate COPD. Methods: We analysed the baseline and 3-year follow-up data from a prospective cohort in China. Patients with mild-to-moderate COPD were enrolled with excluded classic TTs (COPD Assessment Test ≥10, modified Medical Research Council score ≥2, frequent acute exacerbations (AEs) and forced expiratory volume in 1 s (FEV 1 ) % pred 1 decline and a higher risk of total AEs were observed in the AA group, but no differences in FEV 1 decline and total AEs were found in groups with normal spirometry and the group without AAs. Conclusion: The AA group in mild-to-moderate COPD experienced worse image abnormalities, a higher risk of AEs and a faster FEV 1 decline. These results suggest that AAs may be a special TT in patients with mild-to-moderate COPD.
- 10 June 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessImpulse oscillometry-defined airway abnormalities as a treatable trait for mild-to-moderate COPD: a prospective cohort study with 3-year follow-up
Background: Treatable traits (TTs) can effectively conduct personalised assessment and treatment for patients with mild-to-moderate COPD. After excluding the classic TTs, do some neglected TTs remain? We evaluated associations of impulse oscillometry (IOS)-defined airway abnormalities (AAs) with respiratory health outcomes and prognoses in patients with mild-to-moderate COPD. Methods: We analysed the baseline and 3-year follow-up data from a prospective cohort in China. Patients with mild-to-moderate COPD were enrolled with excluded classic TTs (COPD Assessment Test ≥10, modified Medical Research Council score ≥2, frequent acute exacerbations (AEs) and forced expiratory volume in 1 s (FEV 1 ) % pred 1 decline and a higher risk of total AEs were observed in the AA group, but no differences in FEV 1 decline and total AEs were found in groups with normal spirometry and the group without AAs. Conclusion: The AA group in mild-to-moderate COPD experienced worse image abnormalities, a higher risk of AEs and a faster FEV 1 decline. These results suggest that AAs may be a special TT in patients with mild-to-moderate COPD.